Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
Get real-time and historical exchange rates for any currency!
Get real-time and historical stock ticker prices for US stocks!
Translate cryptic bank transactions into merchants with logos, address and more!
Brought to you by Synth, a modern fintech API for modern businesses